Clinical Trials Browser

Phase 3 × Hematologic Neoplasms × cilgavimab and tixagevimab drug combination × Clear all

NCT05438498 2023-09-08

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

Phase 3 Terminated

Other hematologic neoplasm

COVID-19, Hematologic Neoplasms